NCT02097394

The Clinical Study on Combizym and Bifidobacteri to Prevent the Recurrence of Colon Polyps

A Randomized Controlled Study on Combizym and Bifidobacteria to Prevent the Recurrence of Colon Polyps

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 200 (actual)
• Sponsor: RenJi Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The study hypothesis is whether digestion enzyme(Combizym) and intestinal flora drugs(Bifidobacteria) can decease recurrence rate of colon polyps

Detailed description

Colon polyps has high recurrence rate in the digestion diseases. However, the reasons are not clear. The possible reasons for the recurrence of colon polyps include intestinal inflammation (e.g., Ulcerative colitis), intestinal flora imbalance (the benefit intestinal bacteria reduced, which lead to diarrhea or constipation), long-term indigestion. The investigators propose to examine whether digestion enzyme (Combizym) and intestinal flora drugs(Bifidobacteria) can decease recurrence rate of colon polyps

Conditions

• Combizym
• Bifidobacteri
• Colon Polyps

Interventions

Type	Name	Description
DRUG	Combizym	Combizym( 1 tablet, po, tid)
DRUG	Bifidobacteri	Bifidobacteri (2 tablet, po, tid)
DRUG	Combizym + Bifidobacteri	Combizym( 1 tablet, po, tid) + Bifidobacteri (2 tablet, po, tid)

Timeline

• Start date: 2013-06-01
• Primary completion: 2020-06-01
• Completion: 2020-06-01
• First posted: 2014-03-27
• Last updated: 2020-03-05

Locations

1 site across 1 country: China